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Abstract: Heterozygous familial hypercholesterolemia (FH) is a genetic disorder character-
ized by high low-density lipoprotein cholesterol levels from birth, which exposes the arteries 
to high levels of atherogenic lipoproteins lifelong and results in a significantly increased risk 
of premature cardiovascular events. The diagnosis of FH, followed by an appropriate and early 
treatment is critical to reduce the cardiovascular burden in this population. Phase I–III clinical 
trials showed the benefit of proprotein convertase subtilisin kexin 9 inhibitors, both alirocumab 
and evolocumab, in these patients with an average low-density lipoprotein cholesterol reduction 
ranging from −40% to −60%. The aim of this review is to address the unmet needs in cholesterol 
management, elucidate the biology and the clinical benefit of proprotein convertase subtilisin 
kexin 9 inhibition and finally discuss the open gaps and future directions in the treatment of 
patients with heterozygous FH.
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Unmet needs in cholesterol management: focus on 
heterozygous familial hypercholesterolemia
Heterozygous familial hypercholesterolemia (HeFH) is a genetic disorder characterized 
by high low-density lipoprotein cholesterol (LDL-C) levels from birth, which exposes the 
arteries to high levels of atherogenic lipoproteins lifelong and results in a significantly 
increased risk of premature cardiovascular events.1 The diagnosis of familial hyper-
cholesterolemia (FH), followed by appropriate and early treatments aimed at reducing 
LDL-C levels are therefore critical to reduce the cardiovascular burden in this population.
FH is caused primarily by mutations in the gene encoding for the LDL receptor 
(LDLR) which, by affecting its structure and function, cause decreased removal of 
LDL from the circulation. Mutations in the LDLR gene account for ~90% of geneti-
cally determined HeFH, the remaining is due to mutations which alter the binding 
site of apoB to the LDLR, or to other mutations increasing the activity of proprotein 
convertase subtilisin kexin 9 (PCSK9), which cause a decrease in LDLR expression/
activity.2 Heterozygous subjects present with elevated plasma LDL-C levels (200–500 
mg/dL). The frequency of HeFH in the general population has been estimated in 
1:200–250,3 and is higher in selected populations such as patients with premature car-
diovascular disease.4 Despite that, HeFH is still underdiagnosed and, as a consequence, 
undertreated. The homozygous form of FH is much rarer (1:160,000–300,000).5 These 
patients present with very high LDL-C levels (untreated levels >500 mg/dL) and are 
at extremely elevated risk of cardiovascular events.5
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The diagnosis of FH can be done relatively easily by 
using clinical tools such as the Dutch Lipid Clinic Network 
(DLCN) criteria,6 the Make Early Diagnosis to Prevent 
Early Death (MEDPED) criteria,7 or the Simon Broome 
(SB) criteria (Table 1).8 Depending on the specific criteria, 
the score is calculated based on the presence of high LDL-C 
levels, on patient history of premature coronary heart disease 
(CHD) or cerebral or peripheral vascular disease, on family 
history of premature CHD or hypercholesterolemia and on 
the presence of physical signs such as tendon xanthomas or 
corneal arcus. The MEDPED criteria rely on age-specific 
and family relative-specific levels of total cholesterol, but do 
not integrate this information with the clinical characteristics 
of the subjects or the identification of a FH mutation. The 
DLCN score takes into account a family or personal history 
of premature CHD, physical signs, and high LDL-C levels, 
and suggests the genetic analysis if the score is >5; a definite 
FH diagnosis is given when the score is >8. SB criteria are 
similar in terms of parameters evaluated for the score calcula-
tion, giving a definite FH diagnosis in the presence of high 
Table 1 Clinical criteria for the diagnosis of familial hypercholesterolemia
A
Dutch lipid clinic network criteria
Criteria Points
LDL-C values 
>330 mg/dL 8
250–330 mg/dL 5
190–250 mg/dL 3
150–190 mg/dL 1
Personal history
Premature coronary heart disease 2
Premature cerebral or peripheral vascular disease 1
Family history
First-degree relation with premature coronary heart disease 1
Disease
First-degree relation with LDL-C >95th percentile 1
Children <18 years with LDL-C >95th percentile 2
Physical examination
Presence of xanthomas 6
Presence of corneal arcus (<45 years) 4
Genetic tests
Mutation of the LDLR gene 8
B
Simon Broome criteria
Criteria Description
a TC >7.5 mmol/L or LDL-C >4.9 mmol/L in adults, or TC >6.7 mmol/L or LDL-C >4.0 mmol/L in children <16 year
b Tendinous xanthomata in the patient or a first-degree relative
c DNA-based evidence of mutation in the LDLR, APOB, or PCSK9 gene
d Family history of myocardial infarction before age of 50 year in a second-degree relative or before age 60 year in a first-degree relative
e Family history of raised TC >7.5 mmol/L in a first- or second-degree relative
Diagnosis
A definite FH diagnosis requires either criteria a and b or criterion c
A probable FH diagnosis requires criteria a and d or criteria a and e
C
Make Early Diagnosis to Prevent Early Death score
Age 
(years)
First-degree relative with 
FH (total cholesterol 
cutpoints) (mmol/L)
Second-degree relative with 
FH (total cholesterol cutpoints) 
(mmol/L)
Third-degree relative with FH 
(total cholesterol cutpoints) 
(mmol/L)
General population (total 
cholesterol cutpoints) 
(mmol/L)
<20 5.7 5.9 6.2 7.0
20–29 6.2 6.5 6.7 7.5
30–39 7.0 7.2 7.5 8.8
>40 7.5 7.8 8.0 9.3
Note: Diagnosis: FH is diagnosed if total cholesterol levels exceed the cut point.
Abbreviations: FH, familial hypercholesterolemia; LDL-C, low-density lipoprotein cholesterol; TC, total cholesterol. 
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LDL-C (or total cholesterol) levels plus tendon xanthomas 
in the patient or a first or second-degree relative or in the 
presence of a functional mutation in one of the 3 candidate 
genes (Table 1).
Current guidelines suggest to lower LDL-C as early as 
possible in HeFH patients, to delay the onset of the first car-
diovascular event.3,9 Recommended LDL-C goals for these 
patients are levels <100 mg/dL (<2.5 mmol/L) for adults, or 
<70 mg/dL (<1.8 mmol/L) for adults with CHD or diabetes, 
and <135 mg/dL (<3.5 mmol/L) for children.3,9 To this aim, 
several cholesterol-lowering drugs are available; statins are 
the first choice in adults but also in children, in whom only 
those proven to be relatively safe should be used.3,10,11 Statins 
effectively reduce CHD risk in FH subjects,12 however, 
increasing the dose of statins did not result in further LDL-C 
level reduction due to a plateau effect,13,14 which supports the 
need for drugs with a complementary mechanism of action 
to be used in combination with statins to achieve recom-
mended LDL-C targets.3,15 These drugs include ezetimibe, 
mipomersen and lomitapide, or PCSK9 inhibitors.16 In addi-
tion, some patients are statin-intolerant, and this has a special 
relevance in FH patients who need high doses of statins to 
achieve the recommended LDL-C level target. Mipomersen 
and lomitapide are registered for patients with homozygous 
familial hypercholesterolemia (HoFH), while patients with 
HeFH will benefit from the combination statins/ezetimibe, 
which yields an additional reduction of 15%–18%17,18 and, 
more recently, from the monoclonal antibodies directed 
against PCSK9.
PCSK9 biology and strategies to inhibit 
PCSK9
PCSK9 is a serine protease that binds the LDLR and 
promotes its lysosomal degradation19. Through this post-
transcriptional mechanism, PCSK9 limits LDL catabolism 
and increases plasma LDL-C levels.20 PCSK9 also targets 
lipoprotein synthesis in the intestine20 further contributing to 
a disturbed plasma lipid profile. Thus, patients homozygous 
for gain-of-function mutations in PCSK9 gene present the 
clinical phenotype of FH with tendon xanthomas, history 
of CHD, early myocardial infarction, and stroke. On the 
contrary, subjects with loss-of-function mutations in PCSK9 
gene present with lower plasma LDL-C levels and are pro-
tected from coronary artery diseases.21–23 Of note, PCSK9 
plasma levels predict cardiovascular events in statin-treated 
patients with well-controlled LDL levels and documented 
stable coronary artery disease,24 further linking PCSK9 to 
cardiovascular outcomes.
PCSK9 production is mainly regulated by changes in 
cholesterol levels in the liver via the modulation of the nuclear 
translocation of the sterol-responsive element-binding pro-
tein 2 transcription factor.25,26 Once secreted, mature PCSK9 
protein undergoes post-translational modifications that can 
modulate its function, including the cleavage to a truncated 
protein of about 60 kDa by furin or PC5/6A, 2 members of 
the proprotein convertase family.
More importantly, PCSK9 plasma levels increase follow-
ing cholesterol-lowering treatments, a finding observed not 
only with statins but also with ezetimibe.27–29 This mecha-
nism contributes to limiting the pharmacological efficacy of 
statins and other lipid-lowering strategies as well as provides 
a mechanisms for understanding the poor correlation between 
PCSK9 and LDL in circulation.28,29 Therefore, given the role 
of PCSK9 as chaperone in directing the LDLR toward degra-
dation,30 the possibility of inhibiting PCSK9 represents a key 
approach to enhance the lipid-lowering effect of conventional 
agents.30 From a pharmacological perspective, PCSK9 could 
be targeted at different levels from the gene transcription 
(small interfering RNAs, antisense oligonucleotides) to the 
circulating protein (anti-PCSK9 monoclonal antibodies or 
PCSK9 vaccine).30
PCSK9 gene silencing
Gene-silencing approaches are under clinical development, 
and the results from the first Phase II study, ORION-1, with 
a siRNA designed to target PCSK9 (inclisiran) were recently 
published.31 A single injection of the drug results in LDL-C 
reduction up to −36% while the injection of 2 doses (days 
0 and 90) yielded up to −47.2% LDL-C reduction after 240 
days.
Anti-PCSK9 antibodies
Monoclonal antibodies targeted against circulating PCSK9 
have been approved for the treatment of patients at very high 
cardiovascular risk, patients with FH and statin intolerance.
Three antibodies targeting PCSK9 have been devel-
oped (evolocumab, alirocumab, bococizumab) and one, 
LY3015014 is under development.32 Evolocumab and 
alirocumab are commercially available while the develop-
ment of bococizumab has been halted as a reduction in the 
efficacy was observed as a consequence of the induction 
of neutralizing antibodies.33 Results from Phase II studies 
indicated that PCSK9 therapy reduces LDL-C cholesterol 
up to 60%–70%,16 setting the stage for further evaluating 
the benefit of anti-PCSK9 monoclonal antibodies in larger 
cohorts. Anti-PCSK9 therapies not only reduce LDL-C levels 
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but also favor atherosclerotic plaque regression, as evidenced 
by the GLAGOV trial, where in patients with angiographic 
coronary disease treated with statins, addition of evolocumab 
resulted in a −0.95% decrease in percent atheroma volume 
after 76 weeks of treatment.34 More recently, the FOURIER 
trial demonstrated that the inhibition of PCSK9 with evo-
locumab, on a background of statin therapy, reduced the risk 
of cardiovascular events (median duration of follow-up 26 
months) further supporting the benefit of this pharmacologi-
cal strategy.35 The clinical trial for cardiovascular outcomes 
with the other approved antibody, alirocumab, is ongoing 
and the results are expected to be released in early 2018 
(ODYSSEY OUTCOMES). Of note, results on cardiovas-
cular benefits are also available for bococizumab, which, in 
high-risk patients (SPIRE-2 trial), resulted in a significant 
reduction of major cardiovascular events, an effect which 
could not be detected in the trial involving lower risk patients 
(SPIRE-1 trial).36
These data further reinforce the efficacy of lowering 
LDL-C by inhibiting PCSK9 and point to the investigation 
of the efficacy in patients with HeFH.
Clinical trials supporting the use of 
PCSK9 inhibitors in HeFH
Phase I–III clinical trials clearly showed the benefit of PCSK9 
inhibitors, both alirocumab and evolocumab in patients with 
HeFH (Table 2). Data on HeFH patients are available for both.
In the first Phase I trial, alirocumab was tested in 21 
HeFH patients on atorvastatin therapy and LDL-C >100 
mg/dL.37 The average reduction of LDL-C levels was −41% 
at the dose of 50 mg and up to −55% at the dose of 150 
mg. In the 5 patients receiving 150 mg of alirocumab, the 
degree of LDL-C reduction observed, ranged from ~−35% 
to ~−75%. No serious adverse events were reported, with no 
subjects showing increase in alanine transferase or aspartate 
transferase levels and 13% of subjects taking also atorvastatin 
reported an elevation of creatine kinase 3-time higher the 
upper limit of the normal range.
In a larger multicenter, randomized, placebo-controlled, 
Phase II trial, alirocumab was assessed in 77 HeFH patients 
receiving statins with or without ezetimibe and with LDL-C 
>100 mg/dL.38 Patients were randomized to alirocumab 150, 
200, or 300 mg every 4 weeks, 150 mg every 2 weeks, or 
placebo every 2 weeks, and were stratified by concomitant 
use of ezetimibe at baseline. At week 12, LDL-C reductions 
from baseline to week 12 ranged from 29% (150 mg every 
4 weeks) to 68% for alirocumab (150 mg every 2 weeks), 
compared with ~−11% for placebo. Adverse event profiles 
were similar for alirocumab and placebo; the most common 
adverse event was injection-site reaction with one patient in 
the group of alirocumab 300 mg terminating the treatment.
Among Phase III trials with alirocumab, HeFH patients 
were investigated in the ODYSSEY FH I and FH II,39 ODYS-
SEY JAPAN,40 ODYSSEY HIGH FH41 and ODYSSEY 
Table 2 Effects of PCSK9 inhibitors evolocumab and alirocumab in HeFH
Clinical trial Subjects (background LLT) Intervention (dose, 
frequency)
LDL-C (% change 
from baseline)
EVOLOCUMAB
RUTHERFORD45
12 weeks
HeFH, LDL-C ≥100 mg/dL
(statin ± ezetimibe)
420 mg Q4W
−56.4%
RUTHERFORD-246
12 weeks
HeFH, LDL-C ≥100 mg/dL
(statin ± ezetimibe)
140 mg Q2W
420 mg Q4W
−59.2%
−61.3%
ALIROCUMAB
ODYSSEY FH I and FH II39
78 weeks
HeFH,
LDL-C ≥100 mg/dL (for primary prevention) or LDL-C 
≥70 mg/dL (for secondary prevention)
(max tolerated statin ± other LLT)
75 mg Q2W (increased at 150 mg 
Q2W if LDL-C ≥70 mg/dL at 
week 8)
FH I: −57.9%
FH II: −51.4%
ODYSSEY HIGH FH41
78 weeks
HeFH, LDL-C ≥160
(stable LLT)
150 mg Q2W
−39%
ODYSSEY ESCAPE42
18 weeks
HeFH undergoing lipoprotein apheresis
(lipoprotein apheresis + stable LLT + diet + exercise)
150 mg Q2W
−42.5%
ODYSSEY LONG TERM43
78 weeks
HeFH or established CHD or CHD equivalent,
LDL-C≥70 mg/dL
(max tolerated statin ± other LLT)
150 mg Q2w
−61.9%
ODYSSEY OLE
176 weeks
HeFH who have completed one of the 4 parent studies
(max tolerated statin ± other LLT)
ONGOING
Abbreviations: CHD, coronary heart disease; FH, familial hypercholesterolemia; HeFH, heterozygous familial hypercholesterolemia; LDL-C, low-density lipoprotein 
cholesterol; LLT, lipid-lowering therapy; PCSK9, proprotein convertase subtilisin kexin 9; Q4W, every 4 weeks; Q2W, every 2 weeks.
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ESCAPE.42 In ODYSSEY FH I and FH II 735 patients with 
HeFH receiving maximum tolerated statin doses with or 
without other lipid-lowering therapy were enrolled.39 Patients 
were randomized to alirocumab 75 mg every 2 weeks (with 
possible increase to 150 mg at week 12, if LDL-C goal 
was not reached at week 8), or placebo. At week 24, mean 
reductions in LDL-C compared with placebo were 58% in 
FH I and 51% in FH II. Safety and tolerability were gener-
ally comparable in the alirocumab and placebo groups. The 
ODYSSEY JAPAN study included 41 HeFH patients and 
alirocumab treatment resulted in LDL-C reduction similar to 
what was observed with the other studies.40 The ODYSSEY 
HIGH FH trial included 107 patients with severe HeFH, 
(LDL-C levels >160 mg/dL on maximally tolerated statins 
with or without other lipid-lowering therapies).40 Patients 
were randomized to placebo or alirocumab 150 mg every 
2 weeks. At week 24, the relative reduction observed in 
LDL-C was −45.7% compared with −6.6% in the placebo 
group. As seen in other trials, alirocumab was generally well 
tolerated and adverse event rates were generally similar to 
those of the placebo group. The ODYSSEY ESCAPE trial 
evaluated the effect of 12-week treatment with alirocumab 
in HeFH patients undergoing regular lipoprotein apheresis 
every 1 or 2 weeks.42 More than 90% patients on alirocumab 
at least halved the standardized rate of apheresis (−53.7% 
change from baseline at week 6), compared with +1.6% in 
the placebo group,42 and 63.4% of patients on alirocumab 
had not apheresis procedures during 12 weeks.42 In contrast 
to apheresis procedures, characterized by a rapid increase of 
LDL-C levels toward pre-apheresis levels, alirocumab main-
tained LDL-C levels persistently low,42 which may translate 
into a clinical benefit over the long term.
In agreement with this last observation, available data 
indicate that the effect of alirocumab persists over time and 
indeed after 78 weeks of treatment, the results of the ODYS-
SEY LONG TERM study43 showed that LDL-C levels were 
still significantly lower compared with what was observed in 
the placebo group; of note, this study included 415 patients 
with HeFH where the benefit observed was similar to that of 
the entire cohort and in line with what was reported for the 
other studies in HeFH patients.44
A pooled analysis of the safety data for alirocumab studies 
in HeFH patients of treatment was recently published. Data 
are available for more than 800 HeFH patients treated with 
alirocumab versus 418 with placebo (both groups were on 
the maximal tolerated dose of statins + other lipid-lowering 
therapies) up to 78 weeks. Regardless of the alirocumab 
dose, rates of treatment-emergent adverse events (TEAEs) 
were similar in alirocumab (80.5%) and placebo-treated 
patients (83.0%). TEAEs reported in ≥2% of patients receiv-
ing alirocumab were generally comparable with the placebo 
group, except for a higher proportion of patients experienc-
ing injection-site reactions in the alirocumab group (11.4%) 
compared with placebo (8.6%).44
The efficacy and safety of evolocumab in HeFH patients 
were also tested in 2 studies; the RUTHERFORD study was 
a Phase II trial designed to evaluate the effect of evolocumab 
350 or 420 mg versus placebo every 4 weeks in 111 patients 
with clinical diagnosis of FH (SB criteria) and LDL-C lev-
els above 100 mg/dL despite statin therapy with or without 
ezetimibe.45 After 12 weeks of treatment, LDL-C was reduced 
by ~55% with evolocumab 420 mg, compared with a 1% 
increase with placebo (P<0.001).
Four patients in the evolocumab 350 mg group and one 
patient in the 420 mg group were considered poor respond-
ers based on a <15% reduction in LDL-C at week 12.45 
The 3 most common treatment-related adverse events were 
injection-site pain (reported in 3.6% of evolocumab-treated 
patients), headache (1.8%), and skin burning sensation 
(3.6%).45
Evolocumab was further investigated in the Phase III 
RUTHERFORD-2 trial, in which 331 patients with HeFH 
were randomly assigned to evolocumab 140 mg twice a 
month, 420 mg monthly, placebo twice a month, or placebo 
monthly.46 After 12 weeks, evolocumab was associated with 
LDL-C reductions of ~60% compared with the placebo 
group.46 The rate of adverse events was similar between the 
evolocumab and placebo groups and overall evolocumab 
was well tolerated.46
As described above, patients who will benefit from anti-
PCSK9 therapy are, without any doubt, those with HeFH 
while for those with HoFH, the benefit will be linked to 
the mutation underlying the disease. Indeed, based on the 
mechanism of action (a robust induction of LDLR-mediated 
clearance of LDL), the benefit of anti-PCSK9 therapy should 
be more marked in FH patients who retain a partial function-
ality of the LDLR (LDLR defective), while it would be less 
effective in those with a severe mutation of the LDLR (LDLR 
null) or those with other mutations impacting the LDLR axis 
(such as LDLRAP1). On the contrary, it is expected that the 
drug would be highly effective in patients with gain of func-
tion mutations of PCSK9.
For the treatment of HoFH, the TESLA clinical trials have 
specifically addressed the benefit of evolocumab in these 
patients.47,48 A similar observation is available also for ali-
rocumab on HoFH patients, although in a limited cohort: ali-
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rocumab normalizes LDLR expression in  receptor-defective 
HoFH fibroblasts, while no effect is observed in receptor-
negative HoFH.49 An interim subset analysis of the TAUSSIG 
trial confirms the robust and durable reductions in LDL-C 
levels obtained with evolocumab in HoFH patients; in addi-
tion, it provides positive results for subjects receiving apher-
esis in addition to stable lipid-lowering therapy and, even 
more important, for adolescent patients.50 The data indicate 
a reduction of LDL-C levels on the top of available therapies 
of approximately −26%. Although relevant, other drugs with 
different mechanisms of action, such as lomitapide, have 
produced a greater magnitude of reduction in HoFH patients51 
while for mipomersen, the reduction in LDL-C achieved is 
closer to that observed for PCSK9 inhibitors.52
Conclusions and future directions
Available data suggest that HeFH patients would benefit 
most from additional lipid lowering with an anti-PCSK9 
antibody. Data on cardiovascular benefit of evolocumab have 
been recently published (FOURIER trial),35 reporting data on 
overall and cardiovascular mortality as well as the incidence 
of myocardial infarction. The study included patients with 
atherosclerotic cardiovascular disease and LDL-C ≥70 mg/dL 
who were receiving statin therapy.35 A sub-analysis of cardio-
vascular outcome in FH patients enrolled in the study is not 
yet available but it is reasonable to believe that the drugs will 
be as effective in this cohort. However, given the mechanism 
of action of anti-PCSK9, it should be taken into account that 
some HeFH patients with null mutation on the LDL receptor 
will probably experience a minor benefit following mono-
clonal antibody therapy, although the RUTHERFORD-2 
study did not observe different LDL-C lowering response to 
evolocumab in patients with defective or negative LDLR.46 All 
the studies of PCSK9 inhibition in HeFH subjects, in addition, 
reported a good tolerability and rate of adverse events were 
similar between the evolocumab/alirocumab and placebo 
groups (Table 3), as also reported by a recent pooled analysis 
of studies with alirocumab in HeFH patients.44
PCSK9 inhibition was proven to also reduce the levels 
of lipoprotein(a) (Lp(a)), an LDL-like particle, which rep-
resents a cardiovascular risk factor independently of LDL-C 
levels.53 Indeed FH patients, especially those with cardio-
vascular disease, exhibit significantly higher plasma levels 
of Lp(a) compared with their non-affected relatives.54 Lp(a) 
was proposed to play causal role in aortic valve calcifica-
tion development in asymptomatic statin-treated HeFH.55 
These observations support the need to asses Lp(a) levels in 
FH patients to identify those who could benefit from more 
aggressive lipid-lowering treatments.
In contrast to statins, PCSK9 mAbs reduce Lp(a) levels 
by up to 30%,56,57 but the exact mechanism by which such 
reduction takes place is still unclear. LDL-C and Lp(a) levels 
decrease concomitantly during therapy with PCSK9 mAbs, 
and patients achieving lower LDL-C levels also show larger 
Lp(a) reductions.58 Based on these observations, the effect 
on Lp(a) levels in HeFH patients treated with evolocumab 
or alirocumab was evaluated. The RUTHERFORD studies 
reported reductions ranging from −23% up to −31.6% versus 
placebo;45,46 similar reductions were observed in the studies of 
the ODYSSEY program performed in FH subjects (−14.8% 
to −25.6% versus placebo),39,41,43 with the exception of the 
ODYSSEY ESCAPE trial that reported a −4.1% Lp(a) level 
reduction versus placebo.42 Also HoFH showed significant 
Lp(a) level reductions, apparently independent of the genetic 
defect.47,48 The clinical relevance of Lp(a) reduction remains 
to be addressed, however.
Do the achieved very low LDL-C levels pose problems 
of safety? Recently, an analysis of pooled data from 14 
trials on alirocumab indicated that LDL-C levels <25 or 
<15 mg/dL were not associated with a higher incidence of 
treatment-emergent event rates or neurocognitive events,59 
although the incidence of cataract appeared to be increased 
in subjects achieving LDL-C levels <25 mg/dL.59 This find-
ing, however, might be the consequence of the comparison 
of non-randomized subgroups. Due to the need of lifelong 
therapy in patients with FH, the safety of long-term exposure 
to pharmacologically induced very low levels of LDL-C 
remains to be determined.
A final aspect to be considered is the cost-effectiveness 
of anti-PCSK9 therapy in HeFH patients. To date, an 
analysis is available for the US market.60 Adding PCSK9 
inhibitors to statins in HeFH was estimated to prevent 
316,300 major adverse cardiovascular events at a cost of 
Table 3 TEAE frequency in PCSK9 mAbs clinical trials in HeFH 
patients
TEAEs PCSK9 mAbs Placebo
TEAEs (any) 51%–81.7% 28%–82.5%
Serious adverse events 1.8%–18.7% 0%–19.5%
Leading to death 0%–1.9% 0%–1.3%
Leading to treatment discontinuation 0%–7.2% 0%–6.1%
Common adverse events
Injection site reaction 2.4%–12.4% 0%–11%
Nasopharyngitis 7%–13.9% 4%–22.2%
Influenza 4.5%–14.4% 2.9%–10.7%
Headache 4%–9.6% 0%–8.9%
Diarrhea 1.8%–9.8% 0%–8.6%
Nausea 1.8%–4.9% 0%–14.3%
Myalgia 1.9%–9.8% 0%–8.6%
Abbreviations: HeFH, heterozygous familial hypercholesterolemia; mAb, 
monoclonal antibody; PCSK9, proprotein convertase subtilisin kexin 9; TEAEs, 
treatment-emergent adverse events.
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$503.000 per quality-adjusted life year (QALY) gained 
compared with adding ezetimibe to statins.60 Reaching 
the desired QALY threshold of $100.000 will need an 
important reduction of annual drug price. However, a more 
precise determination of the cost-effectiveness of PCSK9 
therapy can only be performed once long-term data on 
clinical outcomes on HeFH patients for PCSK9 inhibitors 
becomes available.
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